Hans-Reinhard Zerkowski

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Universitätsspital Basel provides medical services. It offers medical facilities for the welfare, safety and recovery of patients. The company is headquartered in Basel, Switzerland.

BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.

Novel medical devices for minimal invasive cardiac valve surgery. Medtentia has completed preclinical validation for its first product. Investors Inveni Capital and Industrifonden will take the company through its clinical development phase. Early human trials have been completed successfully Q1 in 2009. Medtentia's technology is patented in USA and patent pending in Europe. Medtentia is a venture-backed medical device company focused on the development of minimally invasive and percutaneous heart valve repair and replacement devices on currently proven therapy. Medtentia will act on a global basis with its core activities and team located to Europe with main office in Helsinki Finland and in the Medicon Valley region of southern Sweden in Lund. Medtentia is currently developing a technology platform of products to enable rapid surgical mitral valve annulus repair and replacement, perform percutaneous mitral repair and replacement, leverage currently accepted therapeutic practice and reduce invasiveness, procedural time and morbidity.

LIFEBRIDGE Medizintechnik AG develops medical technology and produces & markets life-saving support systems which apply state-of-the-art technologies to extracorporeal circulation. It markets its products under the brand name LIFEBRIDGE B2T. The firm has set itself the goal of providing mechanical cardiovascular support to significantly more patients than are receiving such support today in the decisive moments of their lives. This challenge has been taken up by experienced entrepreneurs, engineers, physicians and investors in order, through their know-how and commitment, to set new technological standards in invasive emergency medicine. Acknowledged experts from the worlds of medicine, science and industry are making their crucial contributions with conviction to close life-threatening gaps in the chain of medical care.